Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.
about
Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicFunctional characterization of TcaA: minimal requirement for teicoplanin susceptibility and role in Caenorhabditis elegans virulenceMolecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patientsEpistatic relationships between sarA and agr in Staphylococcus aureus biofilm formation.Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery.Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.Agr function is upregulated by photodynamic therapy for Staphylococcus aureus and is related to resistance to photodynamic therapy.Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.Current and novel antibiotics against resistant Gram-positive bacteriaGenetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates.Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. auBactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: looking for a relationship between tolerance and outcomeEarly agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.Thermodynamics of interactions of vancomycin and synthetic surrogates of bacterial cell wall.Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in miceDaptomycin as supportive treatment option in patients developing mediastinitis after open cardiac surgery.Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycinLarger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicityEmerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes.Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.Microbiology of antibiotic resistance in Staphylococcus aureus.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studiesMulticenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infectionsA review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection.Acquired vancomycin resistance in clinically relevant pathogens.Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Targeting agr- and agr-Like quorum sensing systems for development of common therapeutics to treat multiple gram-positive bacterial infections.A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients.agr Dysfunction and persistent methicillin-resistant Staphylococcus aureus bacteremia in patients with removed eradicable foci.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors.
P2860
Q24614464-C77AF13F-FD4D-4469-BB60-466F7D69627DQ30443507-8122D0D7-7394-489B-9D80-F417120416D2Q33500363-60A855EA-D56F-419A-B3BB-FEE43686A2C7Q33592845-784C9EC1-9A92-4AB9-AAA2-AEA0FFB675CDQ34067779-A82A25DF-7E30-44A4-99DD-EA2E0E3473A9Q34130471-8A9D6172-679F-4765-84F9-F1826BC4135CQ34719034-1E199370-B1B2-4627-8DAC-74FF303D8EFCQ34998629-B2F000EB-B8D6-4D84-8076-7F28C41F038DQ35026521-79E15BA6-F59F-41EE-A24F-CB77B4D9ED53Q35035799-34CDD69A-8F89-432E-9D25-F4C96FCA0A57Q35066896-D762F446-F66C-4153-A1A7-A909DD18A247Q35078077-CCF17F26-5699-4561-B279-DC84DED21250Q35432686-F8BD5E67-C207-4198-84BC-1308B1E6F920Q35814628-0F056E04-9828-4980-B7A4-2069D0C6A190Q35941476-36D1BB89-97D9-4175-86F5-9731847EDB95Q36361545-A5EABB16-4019-4D16-AD7B-43DE65AF5A85Q36452459-24737A5E-234B-4568-AB1B-2441E48CDE25Q36538707-A45E7C69-059B-4F54-AE60-9EEB7CC413B9Q36718474-FA9DDAE6-32BD-43CF-B80A-A9AB8C7C253DQ36777850-032132D2-1401-4EFF-8A8E-7E60F8E82BAEQ36839693-C9BB778B-203F-4390-BCC3-4D32C06A870FQ36861645-13E3D46A-D768-4856-9940-F18EE7DA2276Q36870858-1FCAFE2F-C99D-41A6-9D1D-20A582B8FD7AQ36903680-033FFE32-26FC-4CB3-9609-7D3DD9AF9A0FQ36916064-F412B52F-A12F-42A8-B538-7E7D5BEBE1ECQ37071199-971C2935-6369-4053-A9DE-0810600AE6DAQ37153972-4904F80A-7F14-4CB9-A7BE-C34CC0BF3F0AQ37247772-C23BF0DF-314F-4014-9C7F-92825CAB7FF1Q37252733-C819AFBC-EEA2-439C-9457-C3FB0D865389Q37263399-3E1D103E-294C-434B-BCB8-8ED2FCD6B57CQ37263918-D910F472-CB43-42C8-9DA7-D93723A70738Q37277083-926F667E-8F7D-44E0-A6B7-CFA5A7B1EF6CQ37717901-C24DFDC1-AF1F-4563-A28E-77C3E3D665E5Q37800939-E273B8A0-C4CC-4B89-B941-B5171E57699BQ38100055-38617836-CB4F-493B-88CA-37370C136A6FQ38271273-FF0A683F-B71A-464A-9DF5-E851432491FDQ38457418-5B5A1148-8E82-4EA4-BACC-199A4BF2E84BQ38462842-1CF86828-6405-4AAB-B993-274605BFC9A5Q38880547-0593B9E0-7D9E-4176-A510-DB4C4DC59052Q38897223-2B6C2E37-E7FE-46BD-8C79-BEE03AB44585
P2860
Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Adaptation of methicillin-resi ...... he face of vancomycin therapy.
@ast
Adaptation of methicillin-resi ...... he face of vancomycin therapy.
@en
type
label
Adaptation of methicillin-resi ...... he face of vancomycin therapy.
@ast
Adaptation of methicillin-resi ...... he face of vancomycin therapy.
@en
prefLabel
Adaptation of methicillin-resi ...... he face of vancomycin therapy.
@ast
Adaptation of methicillin-resi ...... he face of vancomycin therapy.
@en
P2093
P356
P1476
Adaptation of methicillin-resi ...... he face of vancomycin therapy.
@en
P2093
George M Eliopoulos
George Sakoulas
Robert C Moellering
P304
P356
10.1086/491713
P407
P478
42 Suppl 1
P577
2006-01-01T00:00:00Z